MyFinsight

HomeCompareAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Privacy Policy
  • Contact

Follow Us

  • Thread
  • X.com
  • Instagram

© 2026 MyFinsight. All rights reserved.

Recent SEC Filings
9/24BLACKBERRY Ltd(BB)9/24PAYCHEX INC(PAYX)9/23GENERAL MILLS INC(GIS)9/22ADOBE INC.(ADBE)9/18KROGER CO(KR)9/24BLACKBERRY Ltd(BB)9/24PAYCHEX INC(PAYX)9/23GENERAL MILLS INC(GIS)9/22ADOBE INC.(ADBE)9/18KROGER CO(KR)
||
||

Cash Flow Overview

Change in Cash
-$1,378K
Free Cash flow
-$8,138K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Stock-based compensation expense
    • Accounts payable
    • Others
Negative Cash Flow Breakdown
    • Accrued liabilities
    • Prepaid expenses
    • Other receivables
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
Net loss
-9,442
-9,243
-28,759
Depreciation of property and equipment
15
16
70
Non-cash lease expense
71
73
288
Stock-based compensation expense
1,788
2,299
3,104
Value of shares issued to consultants
657
730
3,467
Unrealized foreign exchange loss
-7
-13
137
Change in fair value of warrant derivative
0
0
-153
Fair value loss from sepa arrangement
0
-
-388
Value of shares issued for sepa arrangement commitment fees
0
-
440
Other receivables
253
388
-3
Prepaid expenses
742
155
-580
Accounts payable
730
-813
2,932
Accrued liabilities
-894
249
-360
Pancreatic cancer action network (pancan) receivables and payables
-
-
-1,682
Operating lease liabilities
-75
-74
-293
Net cash used in operating activities
-8,138
-7,293
-20,112
Acquisition of property and equipment
0
6
6
Net cash used in investing activities
0
-6
-6
Proceeds from exercise of warrant derivative
-
-
0
Proceeds from issuance of common stock-At The Market Offering Agreement
14,385
-
11,767
Proceeds from issuance of common stock-Standby Equity Purchase Agreement
0
-
2,348
Proceeds from stock option exercise
-
-
32
Other
-
-
-27
Proceeds from at-the-market offering agreements, net of issuance costs
-
7,614
-
Net cash provided by financing activities
6,771
7,614
14,120
Effect of exchange rate changes on cash and cash equivalents
-11
-24
121
Net decrease in cash and cash equivalents
-1,378
291
-5,877
Cash and cash equivalents, beginning of period
5,493
5,202
11,079
Cash and cash equivalents, end of period
4,115
5,493
5,202
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

ONCY Cash Flow Sankey DiagramSankey diagram visualizing ONCY cash flow for the periodProceeds from issuance ofcommon stock-At The...$14,385K Net cash provided byfinancing activities$6,771K Canceled cashflow$7,614K Net decrease in cashand cash...-$1,378K Canceled cashflow$6,771K Stock-based compensationexpense$1,788K Accounts payable$730K Value of shares issuedto consultants$657K Non-cash lease expense$71K Depreciation of property andequipment$15K Unrealized foreignexchange loss-$7K something is missing-$7,614K Net cash used inoperating activities-$8,138K Canceled cashflow$3,268K Effect of exchange ratechanges on cash and cash...-$11K Net loss-$9,442K Accrued liabilities-$894K Prepaid expenses$742K Other receivables$253K Operating leaseliabilities-$75K

ONCOLYTICS BIOTECH INC (ONCY)

ONCOLYTICS BIOTECH INC (ONCY)